Results 11 to 20 of about 94,685 (269)
Clinical Interventions in Aging, 2021 Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease globally. Current estimates are that 24% of the adult population, thus, one billion individuals worldwide, are affected. Interestingly, the prevalence of fatty liver seems to peak between 40─50 years of age in males and 60─69 years in females, often slightly decreasing in ...
Saleh A Alqahtani, Jörn M Schattenberg
openaire +3 more sources
JHEP Reports, 2021 Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology.
Parlati, Lucia +3 more
openaire +3 more sources
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Frontiers in Endocrinology, 2023 The progression of non-alcoholic fatty liver disease (NAFLD), the most common liver disease, leads to non-alcoholic steatohepatitis and hepatocellular carcinoma. Despite the increasing incidence and prevalence of NAFLD, its therapeutic and preventive strategies to lower the disease burden is limited.
Seogsong Jeong +3 more
openaire +3 more sources
Current management of NAFLD [PDF]
Medicine and Pharmacy Reports, 2016 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. It affects about 1 billion individuals worldwide. While people with simple steatosis have no higher risk of death than the general population, people with non-alcoholic steatohepatitis are at increased risk of death compared to general ...
MUNTEANU, MIHAI ALEXANDRU +2 more
openaire +2 more sources
NAFLD: A multisystem disease [PDF]
Journal of Hepatology, 2015 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries that is predicted to become also the most frequent indication for liver transplantation by 2030. Over the last decade, it has been shown that the clinical burden of NAFLD is not only confined to liver-related morbidity and mortality, but ...
CD Byrne, TARGHER, Giovanni
openaire +3 more sources
NAFLD or comorbidities, that is the question [PDF]
Journal of Hepatology, 2020 N ...
Ponziani F. R. +2 more
openaire +3 more sources
Why are there no strategies for NAFLD? [PDF]
Journal of Hepatology, 2022 Byrne, Christopher +2 more
openaire +3 more sources
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Hepatology, EarlyView., 2022 Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu +11 more
wiley +1 more source
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
Hepatology, EarlyView., 2022 Abstract Background and Aims There is an ongoing debate on whether NAFLD is an active contributor or an innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to assess the causal relationship between NAFLD and CAD.
Zhewen Ren +4 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan +22 more
wiley +1 more source